Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Key Points. Pola is an effective treatment in heavily pretreated patients with r/r LBCL, but long-term remissions are rare.Pola serves as a valuable bridging tr

  • 123456 Profile photo of Madelyn

    Polatuzumab successfully bridged 51% of patients to CAR-T in this retrospective study with a 6 months OS of 77.9%.